Participant Basic Agreement (PBA) Opportunity - Threat Agnostic Host-Directed Therapeutics
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEPT OF DEFENSE
Contract Value
Not provided
Codes & Classification
Solicitation Number
-
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AC33
Additional Details
Documents1
The Department of Defense (DoD), through its Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), has issued a Special Notice inviting participation in the HEALER portfolio—a forward-looking initiative focused on the development of threat-agnostic, host-directed therapeutics. This opportunity is structured under a Participant Basic Agreement (PBA) and is designed to foster collaboration across the full spectrum of drug development organizations, including both therapeutic developers and support service providers.
**Purpose and Scope**
The HEALER portfolio aims to create a new generation of medical countermeasures that enhance the body’s intrinsic ability to withstand, mitigate, and recover from the complex physiological impacts associated with CBRN (Chemical, Biological, Radiological, and Nuclear) threats. Recognizing that the pathophysiology of CBRN injuries often overlaps with civilian critical care challenges, the program seeks to develop dual-use therapeutics with both national security and commercial market applications. The overarching goal is to deliver layered physiological protection to the Warfighter by targeting key host systems, thereby ensuring operational effectiveness even under extreme duress.
**Key Requirements and Objectives**
The program is seeking collaborators in two primary categories:
1. **Therapeutic Development Collaborators:** Organizations developing host-directed therapeutic candidates are invited to submit white papers detailing:
- A clear product description, including the mechanism of action, targeted physiological pathways, intended use, and proposed FDA indication.
- Summaries of significant in vivo and in vitro efficacy data, particularly any well-controlled studies in validated animal models relevant to CBRN threats.
- Regulatory and clinical status, including FDA sponsor experience, IND status, and summaries of completed or ongoing clinical trials (Phases I-III), with safety and PK/PD data.
- Manufacturing capabilities, including current scale, GMP status, and strategies for scaling production.
- Company profile, highlighting experience in advanced product development, commercialization, and relevant intellectual property.
2. **Drug Development Support Collaborators:** Service providers such as CROs, CDMOs, and firms with expertise in preclinical testing, clinical trial execution, cGMP manufacturing, regulatory submissions, and advanced modeling are encouraged to submit summaries of:
- Core capabilities and relevant experience with complex biologics or small molecules.
- FDA regulatory experience.
- Available infrastructure and capacity or technology to accelerate advanced medical countermeasure development.
All submissions should not exceed five pages (excluding cover page) and must indicate the entity’s willingness to collaborate with other PBA holders within the HEALER portfolio.
**Program Vision and Expected Deliverables**
The HEALER initiative is centered on building host resilience through therapeutics that provide protection across several critical physiological domains:
- Neurological protection
- Respiratory stabilization
- Immune modulation
- Hematologic and vascular function
- Cellular stress and repair pathways
By integrating these focus areas, the program seeks to establish a robust and diverse portfolio of threat-agnostic capabilities, ultimately empowering the host to recover and maintain function in the face of CBRN exposure.
**Administrative and Organizational Details**
- **Contracting Entity:** Department of Defense (DoD), CPE CBRND
- **NAICS Code:** 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
- **Product Service Code:** AC33
- **Authority:** Awards may be made under 10 U.S.C. §§ 4021, 4022, and 4023, and are not subject to the Competition in Contracting Act of 1984.
- **SAM Registration:** All prospective awardees must be registered in the System for Award Management (SAM) prior to invoicing and through final payment.
- **Contact Information:**
- Hunter Robinson ([email protected])
- Alexander Mayatte ([email protected])
- **Notice Status:** Active
- **Notice URL:** [https://sam.gov/opp/3889ef48e86a415cb5cc149a11f02da5/view](https://sam.gov/opp/3889ef48e86a415cb5cc149a11f02da5/view)
**Special Considerations**
This opportunity is not a traditional procurement but rather a call for collaboration under a PBA, emphasizing flexibility and partnership. The program is open to a wide range of organizations, from established pharmaceutical developers to specialized service providers, and encourages teaming arrangements to maximize innovation and accelerate development timelines. The dual-use nature of the therapeutics sought under this program presents a unique commercial opportunity that extends beyond the defense sector.
**Conclusion**
The HEALER portfolio represents a significant and strategic opportunity for organizations with capabilities in host-directed therapeutic development or advanced drug development support services. By aligning national defense priorities with commercial incentives, the program offers a sustainable pathway for the development and deployment of next-generation medical countermeasures. Interested parties are encouraged to review the full notice and submit a comprehensive white paper in accordance with the outlined requirements.